Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.

Somers EB, O'Shannessy DJ.

Biomark Insights. 2014 May 25;9:29-37. doi: 10.4137/BMI.S15245. eCollection 2014.

2.

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L.

J Ovarian Res. 2013 Apr 17;6(1):29. doi: 10.1186/1757-2215-6-29.

3.

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.

4.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.

Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.

PMID:
18394747
5.

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.

Clin Chem Lab Med. 2012 Apr;50(4):721-5. doi: 10.1515/CCLM.2011.816.

6.

Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.

Boudville N, Paul R, Robinson BW, Creaney J.

Lung Cancer. 2011 Sep;73(3):320-4. doi: 10.1016/j.lungcan.2011.01.011. Epub 2011 Feb 18.

PMID:
21333373
7.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.

PMID:
20075387
8.

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr.

Gynecol Oncol. 2007 Sep;106(3):490-7. Epub 2007 May 25.

9.

Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.

Takata A, Yamauchi H, Toya T, Miyamoto-Kohno S, Iwatatsu Y, Teranaka I, Aminaka M, Yamashita K, Kohyama N.

Toxicol Appl Pharmacol. 2011 Apr 15;252(2):123-9. doi: 10.1016/j.taap.2010.09.026. Epub 2010 Oct 8.

PMID:
20933535
10.

Biomarkers for malignant pleural mesothelioma: current status.

Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A.

Mol Diagn Ther. 2008;12(6):375-90. doi: 10.2165/1250444-200812060-00004. Review.

PMID:
19035624
11.

Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.

Hollevoet K, Speeckaert MM, Decavele AS, Vanholder R, van Meerbeeck JP, Delanghe JR.

Clin Lung Cancer. 2012 Nov;13(6):470-4. doi: 10.1016/j.cllc.2011.12.004. Epub 2012 Mar 2.

PMID:
22386954
12.

Update on biomarkers of acute kidney injury: moving closer to clinical impact?

Schiffl H, Lang SM.

Mol Diagn Ther. 2012 Aug 1;16(4):199-207. doi: 10.2165/11634310-000000000-00000. Review.

PMID:
22650449
13.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

14.

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellström I.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6.

15.

Asbestos-related disease: screening and diagnosis.

Rodríguez Portal JA.

Adv Clin Chem. 2012;57:163-85. Review.

PMID:
22870590
16.

Impact of renal function or folate status on altered plasma homocysteine levels in hypothyroidism.

Ozmen B, Ozmen D, Parildar Z, Mutaf I, Turgan N, Bayindir O.

Endocr J. 2006 Feb;53(1):119-24.

17.

Biomarkers for mesothelioma.

Scherpereel A, Lee YC.

Curr Opin Pulm Med. 2007 Jul;13(4):339-443. Review.

PMID:
17534183
18.

Exon deletion in the MSLN gene encoding MPF/mesothelin precursor protein during Laurasiatherian mammal evolution.

Kim DS, Hahn Y.

Int J Mol Med. 2011 Feb;27(2):289-93. doi: 10.3892/ijmm.2010.573. Epub 2010 Dec 2.

PMID:
21132261
19.

Not all inflammatory markers are linked to kidney function: results from a population-based study.

Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M.

Am J Nephrol. 2012;35(3):288-94. doi: 10.1159/000335934. Epub 2012 Mar 6.

PMID:
22398717
20.

Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study.

Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase M.

Crit Care Med. 2009 Feb;37(2):553-60. doi: 10.1097/CCM.0b013e318195846e.

PMID:
19114878
Items per page

Supplemental Content

Write to the Help Desk